12S142: Abstracts: Spondyloarthritis Including PsA – Treatment I: Axial Spondyloarthritis (0542–0547)

Abstract Moderator(s)

• 

  Marina Magrey, MD

  Professor of Medicine, Division Chief of Rheumatology for University Hospitals
  Case Western Reserve University School of Medicine/University Hospitals
  Richfield, OH, United States

  Disclosure(s): Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing); Janssen: Consultant (Ongoing); Novartis: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing); UCB: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  Juergen Braun, MD

  Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum
  Bochum, Nordrhein-Westfalen, Germany

  Disclosure(s): Galapagos: Advisor or Review Panel Member (Terminated); Lilly: Advisor or Review Panel Member (Terminated); Novartis: Advisor or Review Panel Member (Terminated); UCB: Advisor or Review Panel Member (Terminated)

Oral abstract session.

Presentations:

• 4:30 PM – 4:40 PM Eastern Time

  ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update
  

  Presenting Author: Sofia Ramiro, MD, PhD – Leiden University Medical Center
• 4:40 PM – 4:45 PM Eastern Time

  Q&A
  
• 4:45 PM – 4:55 PM Eastern Time

  An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
  

  Presenting Author: Martin Rudwaleit, MD – University of Bielefeld
• 4:55 PM – 5:00 PM Eastern Time

  Q&A
  
• 5:00 PM – 5:10 PM Eastern Time

  Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
  

  Presenting Author: Atul Deodhar, MD – Oregon Health & Science University
• 5:10 PM – 5:15 PM Eastern Time

  Q&A
  
• 5:15 PM – 5:25 PM Eastern Time

  Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK)
  

  Presenting Author: Cindy Weinstein, MD, PhD – Merck & Co, Inc
• 5:25 PM – 5:30 PM Eastern Time

  Q&A
  
• 5:30 PM – 5:40 PM Eastern Time

  COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine over Two Years in Patients with Ankylosing Spondylitis (CONSUL): An Open-Label, Randomized Controlled, Multicenter Trial
  

  Presenting Author: Fabian Proft, MD – Charité Universityhospital Berlin
• 5:40 PM – 5:45 PM Eastern Time

  Q&A
  
• 5:45 PM – 5:55 PM Eastern Time

  Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers
  

  Presenting Author: Lars Rogge, PhD – Institut Pasteur
• 5:55 PM – 6:00 PM Eastern Time

  Q&A